Detalhe da pesquisa
1.
Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study.
Haematologica
; 102(5): 903-909, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28126962
2.
Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia.
Invest New Drugs
; 33(2): 423-31, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25600050
3.
Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma.
Haematologica
; 105(3): e116-e120, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31320555
4.
Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients.
Invest New Drugs
; 32(5): 985-94, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24875134
5.
Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor.
Adv Ther
; 41(5): 1938-1952, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38494543
6.
Application of hematological toxicity modeling in clinical development of abexinostat (S-78454, PCI-24781), a new histone deacetylase inhibitor.
Pharm Res
; 30(10): 2640-53, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23737346
7.
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.
J Clin Oncol
; 41(3): 555-567, 2023 01 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35658525
8.
Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed/refractory mantle cell lymphoma post BTKi in England.
J Med Econ
; 25(1): 730-740, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35611697
9.
Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study.
Breast Cancer Res Treat
; 120(1): 127-34, 2010 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-20035381
10.
Time dependent modulation of tumor radiosensitivity by a pan HDAC inhibitor: abexinostat.
Oncotarget
; 8(34): 56210-56227, 2017 Aug 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-28915585
11.
Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia.
Leuk Lymphoma
; 58(8): 1880-1886, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27911138
12.
A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors.
Oncotarget
; 8(34): 56199-56209, 2017 Aug 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-28915584
13.
Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I.
Eur J Cancer
; 49(13): 2791-7, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23790467